Novavax scores narrower Covid vaccine approval
Digest more
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by Novavax,
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk," the agency said in an article published by The New England Journal of Medicine, authored by FDA Commissioner Dr. Martin Makary and his new top vaccines official, Dr. Vinay Prasad.
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.